COPD: LPS neutrophil chemotaxis model (inhaled)
A key hallmark of COPD is airway neutrophilia – administration of LPS induces neutrophil chemotaxis to the lungs.
In the short (1 day) acute model of inflammation, LPS can be administered as either a nebulized aerosol or via the intratracheal route.
Validated positive controls – budesonide, dexamethasone, roflumilast and fluticasone propionate.
SD rat, Balb/c mouse, C57BL/6J mouse, guinea pig
|LPS induced Neutrophil Chemotaxis
|Assessing novel anti-inflammatories
|BAL differential cell counts and BAL cytokines
Study data generated by Labcorp Huntingdon Pharmacology.